Lightnews — Scholar-powered news

Hans-Joachim Anders @hjanders.bsky.social · 2d

Now open access in @ndt-era.bsky.social

How can we target the production of pathogenic IgA in IgAN?

🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells

▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262

1 2

Hans-Joachim Anders @hjanders.bsky.social · 9d

Now online in @ndt-era.bsky.social

Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI

🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.

▶️ academic.oup.com/ndt/article-...

1 2

Hans-Joachim Anders @hjanders.bsky.social · 12d

Now open access in @ndt-era.bsky.social

Prevalence of Strongyloides stercoralis in HD pts in Vienna

🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe.

▶️ academic.oup.com/ndt/article/...

1 2

Hans-Joachim Anders @hjanders.bsky.social · 12d

Now open access in @ndt-era.bsky.social

QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD

🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting

▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915

Hans-Joachim Anders @hjanders.bsky.social · 21d

Now open access in @NDTsocial

Anti-GBM disease - Treatment Standard

🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment

▶️ academic.oup.com/ndt/article/...

1 3 3

Hans-Joachim Anders @hjanders.bsky.social · 23d

Now open access in @ndt-era.bsky.social

Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations

🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D.

▶️ academic.oup.com/ndt/article/...

Hans-Joachim Anders @hjanders.bsky.social · 26d

Now open access in @ndt-era.bsky.social al

CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA

🧐Check also our 2 open access editorials on this innovative concept.

▶️ academic.oup.com/ndt/article/...

1 3

Hans-Joachim Anders @hjanders.bsky.social · 28d

Now online in @ndt-era.bsky.social

Transition of pts with hereditary nephropathies from pediatric to adult care
from WG Genes&Kidney of ERA and ESPN

🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD.

▶️ academic.oup.com/ndt/article-...

1 3

Hans-Joachim Anders @hjanders.bsky.social · 28d

New RCT online in @ndt-era.bsky.social

Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade

🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN

▶️ academic.oup.com/ndt/article-...

1 1

Hans-Joachim Anders @hjanders.bsky.social · Sep 8

Now open access in @ndt-era.bsky.social

Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD

🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD.

▶️ academic.oup.com/ndt/article/...

Reposted by Hans-Joachim Anders

AIN/Sandipan Shringi @nephrosage.bsky.social · Sep 5

Which agent are you using in post kidney transplant dyslipidemia? statin, ezetimibe, PCSK9 modulators or bempedoic acid?
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social

Lipid-lowering agents in solid organ transplant recipients

ABSTRACT. Although pre- and post-transplant dyslipidaemia is one of the most prevalent modifiable risk factors associated with an increased risk of major c

academic.oup.com

1 4

Reposted by Hans-Joachim Anders

AIN/Sandipan Shringi @nephrosage.bsky.social · Sep 4

Acute kidney injury, acute kidney disease and chronic kidney disease: challenges and research perspectives
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social

1 5

Reposted by Hans-Joachim Anders

AIN/Sandipan Shringi @nephrosage.bsky.social · Sep 3

A step toward personalized medicine
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social, @Richard Glassock, @Andrew Rule, @Aleksandar Denic, @delanaye.bsky.social

1 2

Hans-Joachim Anders @hjanders.bsky.social · Aug 16

Now online in @ndt-era.bsky.social

Cost-effectiveness of protein restricted diets in advanced CKD

🧐In pts adherent to diet prescription, low-protein diets delay the start of dialysis, improve survival, and save money

▶️ academic.oup.com/ndt/article-...

Cost-effectiveness of protein restricted diets in advanced CKD

AbstractBackground. The dialysis costs are not sustainable everywhere, resulting in many avoidable deaths. Interventions that postpone the start of dialysi

academic.oup.com

4

Hans-Joachim Anders @hjanders.bsky.social · Aug 16

Now open access in @ndt-era.bsky.social

Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications

🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies

▶️ academic.oup.com/ndt/article/...

8 19

Hans-Joachim Anders @hjanders.bsky.social · Aug 13

Now open access in @ndt-era.bsky.social

What do RCTs teach us about the pathophysiology of human IgAN?

🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.

▶️ academic.oup.com/ndt/article/...

1 5

Hans-Joachim Anders @hjanders.bsky.social · Aug 12

Beautiful, please consider to submit to www.era-online.org/ndt-kidney-a... with the option to be selected for the cover page of @ndt-era.bsky.social

NDT Kidney Art Gallery | ERA

This collection by NDT’s creative readers and artists offers a unique glimpse into the complex structures and functions of the kidneys.

www.era-online.org

1 2

Hans-Joachim Anders @hjanders.bsky.social · Aug 12

Now online in @ndt-era.bsky.social

Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease

🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD

▶️ academic.oup.com/ndt/article-...

2 2

Hans-Joachim Anders @hjanders.bsky.social · Aug 11

Now open access in @ndt-era.bsky.social

Evolving strategies for early diagnosis, proactive prevention and treatment of CKD

🧐"Inferior doctors provide KRT
Mediocre doctors treat CKD
Superior doctors prevent kidney disease"

▶️
academic.oup.com/ndt/article/...

1

Reposted by Hans-Joachim Anders

Mo. Elrggal @kidneyman.bsky.social · Jul 13

Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com
academic.oup.com/ndt/article/...

1 2

Hans-Joachim Anders @hjanders.bsky.social · Jul 13

Now online in @ndt-era.bsky.social

Acute post-streptococcal GN (in children) - treatment standard

🧐 Pathophysiology, diagnosis, outcome prediction, and management standard

▶️ academic.oup.com/ndt/article-...

2

Hans-Joachim Anders @hjanders.bsky.social · Jul 12

Now online in @ndt-era.bsky.social

Multifactorial chronic kidney disease

🧐 Life is long and our kidneys have to take many hits, hence, adult CKD is usually multifactorial as is atherosclerosis or dementia. RF control is key and RF vary across world regions

▶️ academic.oup.com/ndt/article-...

3

Hans-Joachim Anders @hjanders.bsky.social · Jul 12

Now online in @ndt-era.bsky.social

Treatment standard: CKD in the geriatric patient

🧐Pat.-centered communication about preferences and prioritized Tx goals sonsiders psychosocial factors and home environment, as well as their medical needs and prognosis

▶️ academic.oup.com/ndt/article-...

3

Reposted by Hans-Joachim Anders

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Jul 7

Following on CONFIDENCE (on #NephJC tomorrow)

The design and baseline data from MIRO-CKD trial

academic.oup.com/ndt/advance-...

N = 614, balcinerone, dapagliflozin
Urine ACR outcome

#NephSky

3 8

Reposted by Hans-Joachim Anders

Nephrology Journal Club @nephjc.bsky.social · Jun 25

T0d: #NephJC

CKD’s story is shifting- RASi, flozins, MRAs, and GLP-1s have redrawn the map, turning a therapeutic desert into a landscape of cardio-renal possibility

Relevant infographic from @brendonneuen.bsky.social‬

academic.oup.com/ndt...

2 7 15